Welcome to our dedicated page for Acelyrin news (Ticker: SLRN), a resource for investors and traders seeking the latest updates and insights on Acelyrin stock.
ACELYRIN, INC. (Nasdaq: SLRN) features prominently in news coverage as a late-stage clinical biopharma company focused on immunology and immune-mediated diseases. Company announcements emphasize its lead program, lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R that is being investigated for the treatment of thyroid eye disease (TED), and its strategic plans to combine with Alumis Inc. (Nasdaq: ALMS) in an all-stock merger.
News about SLRN frequently centers on clinical trial progress and program design. ACELYRIN has reported additional Phase 2 data for lonigutamab in TED, including clinically meaningful improvements across TED manifestations and a safety profile that, according to the company, has not shown certain adverse events in the data disclosed. The company has also outlined its Phase 3 LONGITUDE program, with two global, double-masked, placebo-controlled trials designed to evaluate subcutaneous lonigutamab in both active and chronic TED patients.
Another major theme in ACELYRIN news is corporate strategy and transactions. Multiple releases describe a definitive merger agreement with Alumis to create a combined late-stage clinical biopharma company dedicated to therapies for immune-mediated diseases. Updates cover the original merger announcement, reaffirmations of the strategic and financial rationale, an amended merger agreement that adjusts the exchange ratio, and the approval of the merger agreement by ACELYRIN stockholders at a special meeting.
Investors following SLRN news will also see coverage of governance and stockholder matters, including ACELYRIN’s adoption of a limited-duration stockholder rights plan and its evaluation of an unsolicited indication of interest from Concentra Biosciences. Together, these items provide context on both the development of lonigutamab and the evolving corporate structure as ACELYRIN moves toward its planned combination with Alumis.
ACELYRIN announced that positive proof-of-concept data from its Phase 1/2 trial of lonigutamab, a subcutaneous anti-IGF-1R antibody, will be presented at the Endocrine Society's Annual Meeting (ENDO 2024) in Boston. Lonigutamab is designed to treat thyroid eye disease (TED). The presentation, led by Dr. Shoaib Ugradar, will take place on June 3, 2024, from 2:00pm to 2:15pm ET. This announcement is significant as lonigutamab is the first subcutaneous treatment to show clinical responses in TED patients, utilizing the only FDA-approved mechanism for the disease.
ACELYRIN, INC. provided a business update, highlighting milestones such as completing enrollment in Phase 3 trials and reporting positive data for lonigutamab and izokibep. The company aims to accelerate the development of transformative medicines while maintaining financial stability. Changes in the leadership team were also announced.
ACELRYIN, INC. announced a leadership transition with Mina Kim appointed as the new CEO and board member, replacing founder Shao-Lee Lin, who stepped down. The company focuses on developing transformative medicines in immunology and has seen early positive data in clinical trials. Shep Mpofu becomes the Chief Medical Officer, Gil Labrucherie takes on the role of Chief Business Officer, in addition to being the CFO, and Sanam Pangali is named Chief Legal Officer and Head of People.
On May 13, 2024, ACELYRIN, INC. (SLRN) will host a conference call to discuss its first quarter 2024 financial results and corporate update. The company focuses on transformative medicines in immunology, with a live webcast and replay available on its website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.